BiotechTube

Cabozantinib

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Salivary Gland Cancer

Conditions

Salivary Gland Cancer

Trial Timeline

Sep 5, 2018 → Nov 6, 2019

NCT ID
NCT03729297

About Cabozantinib

Cabozantinib is a phase 2 stage product being developed by Ipsen for Salivary Gland Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03729297. Target conditions include Salivary Gland Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (8)

NCT IDPhaseStatus
NCT06341712Phase 2Active
NCT06548867Pre-clinicalRecruiting
NCT05660954Phase 2Active
NCT04511455Phase 2Completed
NCT04204850Phase 2Recruiting
NCT03945773Phase 2Completed
NCT04510688Pre-clinicalCompleted
NCT03729297Phase 2Terminated

Competing Products

11 competing products in Salivary Gland Cancer

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
enzalutamideAstellas PharmaPhase 2
52
GefitinibAstraZenecaPhase 2
52
Goserelin Acetate + PembrolizumabMerckPhase 2
52
DovitinibNovartisPhase 2
52
Sacituzumab govitecanGilead SciencesPhase 2
51
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Ipilimumab + NivolumabBristol Myers SquibbPhase 2
51
Darolutamide + GoserelinBayerPhase 2
49
IvonescimabSummit TherapeuticsPhase 2
49
AVA6000Avacta GroupPhase 1
25

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82